Orchestra BioMed (US:OBIO) ZACKSยท2025-05-12 22:41Company Performance - Orchestra BioMed Holdings, Inc. reported a quarterly loss of $0.49 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.46, and compared to a loss of $0.38 per share a year ago, indicating a decline in performance [1] - The company posted revenues of $0.87 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 122.56%, and up from $0.62 million in the same quarter last year [2] - Over the last four quarters, the company has surpassed consensus EPS estimates only once, and has topped consensus revenue estimates two times [2] Stock Performance - Shares of Orchestra BioMed Holdings, Inc. have declined approximately 33.8% since the beginning of the year, while the S&P 500 has only declined by 3.8% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.49 on revenues of $0.61 million, and for the current fiscal year, it is -$1.99 on revenues of $2.5 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Orchestra BioMed belongs, is currently ranked in the top 34% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor sentiment and stock performance [5]